As lead product Flurizan is being tested in a Phase III trial for Alzheimer's disease, Myriad Genetics Inc. priced a public offering of its common stock to raise $129.5 million. (BioWorld Today)
Abgenix Inc.'s stock surged 37.7 percent Thursday following news that its EGFr inhibitor, panitumumab, significantly improved progression-free survival in a pivotal metastatic colorectal cancer study. (BioWorld Today)
Ending a 2-year-old dispute, Cambridge Antibody Technology plc and Abbott Laboratories reached an agreement concerning Humira royalties payable to CAT under a 1995 deal. (BioWorld International)
As scares of an avian flu pandemic circulate following recent cases in Southeast Asia and parts of Europe, the U.S. government has awarded a $62.5 million vaccine contract to Chiron Corp. (BioWorld Today)
Nearly three months after raising $135 million to move its lead blood-clotting agent into a pivotal study, ZymoGenetics Inc. started the Phase III trial of recombinant human Thrombin (rhThrombin) in surgery patients. (BioWorld Today)
Ending a 2-year-old dispute, Cambridge Antibody Technology plc and Abbott Laboratories reached an agreement concerning Humira royalties payable to CAT under a 1995 deal. (BioWorld Today)
